Ayer Mesut, Sakin Abdullah, Ay Selim, Ayer Aylin, Sazak Elif Gökçen, Aktan Melih
Haseki Training and Research Hospital, Clinic of Hematology, İstanbul, Turkey, Phone: +90 212 529 44 00/2048, E-mail:
Turk J Haematol. 2016 Dec 1;33(4):335-338. doi: 10.4274/tjh.2016.0075. Epub 2016 Apr 18.
Chronic lymphocytic leukemia (CLL) is a disease of nonproliferating and mature-appearing B lymphocytes. Insulin-like growth factor-1 (IGF-1) is a small peptide hormone and has mitogenic and antiapoptotic effects, and insulin-like growth factor binding protein-3 (IGFBP-3) has antiproliferative effects on cells. In this study, we investigated plasma levels of both IGF-1 and IGFBP-3 in patients with CLL compared with controls, and we compared these plasma levels according to prognostic factors.
Patients with newly diagnosed CLL who were being followed at the Haseki Training and Research Hospital, İstanbul, Turkey, and volunteers were included in this study. Patients were stratified according to the Rai staging system. Statistical analysis was conducted using SPSS 17.0 for Windows.
Forty-three patients [16 women (37%) and 27 men (63%)] were enrolled in this study. Twenty-one volunteers (11 women, 10 men) were included in the control group. The median age of the patients was 65±9 years (range: 18-63 years), and subjects in the control group were 68±8 years old (range: 18-63 years). Even though the plasma levels of IGF-1 were higher and those of IGFBP-3 were lower and the ratio of IGF-I/IGFBP-3 was higher in comparison with the control group, these differences were not statistically significant (p>0.05). In the study group, IGF-1 levels appeared to be increased in parallel to more advanced Rai stages. There were no significant differences between the other groups (p=0.105).
Plasma IGF-I levels were found higher in patients than in the control group and plasma IGFBP-3 levels were lower; however, neither result was statistically significant. Plasma IGF level increment was observed in concordance with Rai staging. These results prompted us to think that plasma IGF-1 levels in CLL patients are correlated with tumor burden and Rai staging and therefore could be a valuable prognostic factor. Further comprehensive studies are required to support our results.
慢性淋巴细胞白血病（CLL）是一种非增殖性且外观成熟的B淋巴细胞疾病。胰岛素样生长因子-1（IGF-1）是一种小肽激素，具有促有丝分裂和抗凋亡作用，而胰岛素样生长因子结合蛋白-3（IGFBP-3）对细胞具有抗增殖作用。在本研究中，我们调查了CLL患者与对照组相比血浆中IGF-1和IGFBP-3的水平，并根据预后因素比较了这些血浆水平。
本研究纳入了在土耳其伊斯坦布尔哈塞基培训与研究医院接受随访的新诊断CLL患者以及志愿者。患者根据Rai分期系统进行分层。使用SPSS 17.0 for Windows进行统计分析。
本研究共纳入43例患者[16例女性（37%）和27例男性（63%）]。对照组纳入21名志愿者（11名女性，10名男性）。患者的中位年龄为65±9岁（范围：18 - 63岁），对照组受试者年龄为68±8岁（范围：18 - 63岁）。尽管与对照组相比，CLL患者血浆中IGF-1水平较高，IGFBP-3水平较低，IGF-I/IGFBP-3比值较高，但这些差异无统计学意义（p>0.05）。在研究组中，IGF-1水平似乎随着Rai分期的进展而升高。其他组之间无显著差异（p = 0.105）。
发现患者血浆IGF-I水平高于对照组，血浆IGFBP-3水平低于对照组；然而，两者结果均无统计学意义。观察到血浆IGF水平的升高与Rai分期一致。这些结果促使我们认为CLL患者的血浆IGF-1水平与肿瘤负荷和Rai分期相关，因此可能是一个有价值的预后因素。需要进一步的综合研究来支持我们的结果。
